Changing the standard of care in previously treated metastatic renal cell carcinoma

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, from Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.

Share this video  
Similar topics